A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors
NCT ID: NCT02667873
Last Updated: 2025-02-10
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
72 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-02-23
Study Completion Date
2021-10-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study SL-801-0115 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-801 in participants with advanced solid tumors.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors
NCT05382936
Advanced Solid Tumor
TERMINATED
PHASE1
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279
Glioblastoma
Melanoma Stage IV
Breast Cancer
+11 more
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors
NCT00842335
Advanced Solid Tumors
COMPLETED
PHASE1/PHASE2
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination
NCT05525247
Advanced Solid Tumor
RECRUITING
PHASE1/PHASE2
Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors
NCT06563375
Solid Tumor
RECRUITING
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study SL-801-0115 is a first-in-human, dose-escalation study in participants with advanced (that is, metastatic or locally advanced and unresectable) solid tumors that are resistant to or relapsed following available standard systemic therapy or for which there is no standard systemic therapy and additional radiation therapy, or other loco-regional therapies are not considered feasible. Eligible participants will be enrolled and receive treatment with SL-801. SL-801 will be administered orally, and the dose regimen will depend on the cohort in which the participant is enrolled.
The study plans to enroll approximately 70 adult participants at multiple study centers in the United States.
The study plans to enroll approximately 70 adult participants at multiple study centers in the United States.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Solid Tumors
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SL-801
The starting dose regimen of SL-801 (that is, the dose regimen in Cohort 1) is 5 milligrams (mg)/day on Days 1-4 and 8-11 every 21 days. In the second portion of the dose escalation stage, participants receive SL-801 orally once daily on days 1-2, 8-9, 15-16 and 22-23 every 28 days. The starting dose will be 70 mg/day (the next planned dose level). The SL-801 dose regimen for a particular participant is dependent on the cohort in which the participant is enrolled.
Group Type
EXPERIMENTAL
SL-801
Intervention Type
DRUG
SL-801 is a small-molecule inhibitor of the nuclear export protein Exportin-1 (XPO1).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SL-801
SL-801 is a small-molecule inhibitor of the nuclear export protein Exportin-1 (XPO1).
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Felezonexor
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The participant must have histologic or cytologic evidence of a malignant solid tumor and must have disease that is resistant to or relapsed following available standard systemic therapy, or for which there is no standard systemic therapy or reasonable therapy likely to result in clinical benefit.
* The participant must have advanced disease, defined as cancer that is either metastatic, or locally advanced and unresectable (and for which additional radiation therapy or other locoregional therapies are not considered feasible).
* The participant must have disease that is measurable by standard imaging techniques, per the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), or evaluable per RECIST 1.1. (For participants with prior radiation therapy, measurable lesions must be outside of any prior radiation field\[s\], unless disease progression has been documented at that disease site subsequent to radiation.)
* The participant is ≥18 years old.
* The participant has an Eastern Cooperative Oncology Group Performance Status of 0-2.
* The participant has adequate baseline organ function, as demonstrated by the following:
* Serum creatinine ≤1.5 × institutional upper limit of normal (ULN) or calculated creatinine clearance \>30 milliliters (mL)/minute.
* Serum albumin ≥2.5 grams/deciliter (g/dL).
* Bilirubin ≤1.5 × institutional ULN.
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × institutional ULN (participants with hepatic metastases must have AST/ALT ≤5 times ULN).
* International normalized ratio ≤1.5 or prothrombin time ≤1.5 × ULN; and either partial thromboplastin time or activated partial thromboplastin time (partial thromboplastin time or activated partial thromboplastin time) ≤1.5 × ULN.
* The participant has adequate baseline hematologic function, as demonstrated by the following:
* Absolute neutrophil count ≥1.5×10\^9/liter (L)
* Hemoglobin ≥8 g/dL, with no red blood cell transfusions within the prior 14 days.
* Platelet count ≥100×10\^9/L, with no platelet transfusions within the prior 14 days.
* If the participant is a woman of childbearing potential, she has had a negative serum or urine pregnancy test within 1 week prior to treatment.
* The participant (male and female) agrees to use acceptable contraceptive methods for the duration of time on the study and continue to use acceptable contraceptive methods for 1 month after the last dose of SL-801.
* The participant has signed informed consent prior to initiation of any study-specific procedures or treatment.
* The participant is able to adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment.
* The participant must have advanced disease, defined as cancer that is either metastatic, or locally advanced and unresectable (and for which additional radiation therapy or other locoregional therapies are not considered feasible).
* The participant must have disease that is measurable by standard imaging techniques, per the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), or evaluable per RECIST 1.1. (For participants with prior radiation therapy, measurable lesions must be outside of any prior radiation field\[s\], unless disease progression has been documented at that disease site subsequent to radiation.)
* The participant is ≥18 years old.
* The participant has an Eastern Cooperative Oncology Group Performance Status of 0-2.
* The participant has adequate baseline organ function, as demonstrated by the following:
* Serum creatinine ≤1.5 × institutional upper limit of normal (ULN) or calculated creatinine clearance \>30 milliliters (mL)/minute.
* Serum albumin ≥2.5 grams/deciliter (g/dL).
* Bilirubin ≤1.5 × institutional ULN.
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × institutional ULN (participants with hepatic metastases must have AST/ALT ≤5 times ULN).
* International normalized ratio ≤1.5 or prothrombin time ≤1.5 × ULN; and either partial thromboplastin time or activated partial thromboplastin time (partial thromboplastin time or activated partial thromboplastin time) ≤1.5 × ULN.
* The participant has adequate baseline hematologic function, as demonstrated by the following:
* Absolute neutrophil count ≥1.5×10\^9/liter (L)
* Hemoglobin ≥8 g/dL, with no red blood cell transfusions within the prior 14 days.
* Platelet count ≥100×10\^9/L, with no platelet transfusions within the prior 14 days.
* If the participant is a woman of childbearing potential, she has had a negative serum or urine pregnancy test within 1 week prior to treatment.
* The participant (male and female) agrees to use acceptable contraceptive methods for the duration of time on the study and continue to use acceptable contraceptive methods for 1 month after the last dose of SL-801.
* The participant has signed informed consent prior to initiation of any study-specific procedures or treatment.
* The participant is able to adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment.
Exclusion Criteria
* The participant has persistent clinically significant ≥Grade 2 toxicities from previous anticancer therapy (excluding Grade 2 chemotherapy-related neuropathy which is permitted, and excluding Grade 2-3 laboratory abnormalities if they are not associated with symptoms, are not considered clinically significant by the Investigator, and can be managed with available medical therapies).
* The participant has received treatment with chemotherapy, external-beam radiation, or other systemic anticancer therapy within 28 days prior to study entry (Participants with advanced prostate cancer who are receiving luteinizing hormone releasing hormone \[LHRH\] agonists are permitted onto the study and should continue use of these agents during study treatment).
* The participant has received treatment with an investigational systemic anticancer agent within 28 days prior to C1D1.
* The participant has previously received treatment with SL-801 or another investigational agent that inhibits the XPO1/CRM1 pathway.
* The participant has an additional active malignancy that may confound the assessment of the study endpoints. Participants with a past cancer history (active malignancy within 2 years prior to study entry) with substantial potential for recurrence must be discussed with the Sponsor before study entry. Participants with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ (including transitional cell carcinoma, cervical intraepithelial neoplasia), organ-confined prostate cancer with no evidence of progressive disease.
* The participant has clinically significant cardiovascular disease (for example, uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months prior to study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).
* The participant has uncontrolled, clinically significant pulmonary disease (for example, chronic obstructive pulmonary disease, pulmonary hypertension) that, in the Investigator's opinion, would put the participant at significant risk for pulmonary complications during the study.
* The participant has known active or suspected brain or leptomeningeal metastases. (Central nervous system \[CNS\] imaging is not required prior to study entry unless there is a clinical suspicion of CNS involvement). Participants with stable, treated brain metastases are eligible provided there is no evidence of CNS disease growth on imaging for at least 3 months following radiation therapy or other locoregional ablative therapy to the CNS.
* The participant is receiving immunosuppressive therapy for prophylaxis following a prior organ transplant (solid organ or allogeneic stem cell) or management of immune-mediated toxicities due to immunotherapy. Low-dose corticosteroid (defined as \< 10 mg/day of prednisone or equivalent) therapy is permitted.
* The participant has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit compliance with study requirements.
* The participant is pregnant or breast feeding.
* The participant has known positive status for human immunodeficiency virus active or chronic Hepatitis B or Hepatitis C.
* The participant is oxygen dependent.
* The participant has any medical condition which in the opinion of the Investigator places the patient at an unacceptably high risk for toxicities.
* The participant has received treatment with chemotherapy, external-beam radiation, or other systemic anticancer therapy within 28 days prior to study entry (Participants with advanced prostate cancer who are receiving luteinizing hormone releasing hormone \[LHRH\] agonists are permitted onto the study and should continue use of these agents during study treatment).
* The participant has received treatment with an investigational systemic anticancer agent within 28 days prior to C1D1.
* The participant has previously received treatment with SL-801 or another investigational agent that inhibits the XPO1/CRM1 pathway.
* The participant has an additional active malignancy that may confound the assessment of the study endpoints. Participants with a past cancer history (active malignancy within 2 years prior to study entry) with substantial potential for recurrence must be discussed with the Sponsor before study entry. Participants with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ (including transitional cell carcinoma, cervical intraepithelial neoplasia), organ-confined prostate cancer with no evidence of progressive disease.
* The participant has clinically significant cardiovascular disease (for example, uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months prior to study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).
* The participant has uncontrolled, clinically significant pulmonary disease (for example, chronic obstructive pulmonary disease, pulmonary hypertension) that, in the Investigator's opinion, would put the participant at significant risk for pulmonary complications during the study.
* The participant has known active or suspected brain or leptomeningeal metastases. (Central nervous system \[CNS\] imaging is not required prior to study entry unless there is a clinical suspicion of CNS involvement). Participants with stable, treated brain metastases are eligible provided there is no evidence of CNS disease growth on imaging for at least 3 months following radiation therapy or other locoregional ablative therapy to the CNS.
* The participant is receiving immunosuppressive therapy for prophylaxis following a prior organ transplant (solid organ or allogeneic stem cell) or management of immune-mediated toxicities due to immunotherapy. Low-dose corticosteroid (defined as \< 10 mg/day of prednisone or equivalent) therapy is permitted.
* The participant has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit compliance with study requirements.
* The participant is pregnant or breast feeding.
* The participant has known positive status for human immunodeficiency virus active or chronic Hepatitis B or Hepatitis C.
* The participant is oxygen dependent.
* The participant has any medical condition which in the opinion of the Investigator places the patient at an unacceptably high risk for toxicities.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stemline Therapeutics, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yale Cancer Center
New Haven, Connecticut, United States
Site Status
Florida Cancer Specialist
Sarasota, Florida, United States
Site Status
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Site Status
Mary Crowely Cancer Research Centers- Medical City
Dallas, Texas, United States
Site Status
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Site Status
University of Washington, Seattle Cancer Care Alliance
Seattle, Washington, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Ahn C. An evaluation of phase I cancer clinical trial designs. Stat Med. 1998 Jul 30;17(14):1537-49. doi: 10.1002/(sici)1097-0258(19980730)17:143.0.co;2-f.
Reference Type
BACKGROUND
Arnaoutov A, Azuma Y, Ribbeck K, Joseph J, Boyarchuk Y, Karpova T, McNally J, Dasso M. Crm1 is a mitotic effector of Ran-GTP in somatic cells. Nat Cell Biol. 2005 Jun;7(6):626-32. doi: 10.1038/ncb1263.
Reference Type
BACKGROUND
Dillman RO, Koziol JA. Phase I cancer trials: limitations and implications. Mol Biother. 1992 Sep;4(3):117-21.
Reference Type
BACKGROUND
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
Reference Type
BACKGROUND
Gatsonis C, Greenhouse JB. Bayesian methods for phase I clinical trials. Stat Med. 1992 Jul;11(10):1377-89. doi: 10.1002/sim.4780111011.
Reference Type
BACKGROUND
Gerecitano J. SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents. J Hematol Oncol. 2014 Oct 4;7:67. doi: 10.1186/s13045-014-0067-3.
Reference Type
BACKGROUND
Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH, Sun YJ. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med. 2009 Dec 1;32(6):E315.
Reference Type
BACKGROUND
International Conference on Harmonisation. E8: General Considerations for Clinical Trials, July 1997.
Reference Type
BACKGROUND
Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Kantarjian H, Shacham S, Kauffman M, Andreeff M. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013 May 16;121(20):4166-74. doi: 10.1182/blood-2012-08-447581. Epub 2013 Apr 5.
Reference Type
BACKGROUND
Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, Lucas D, Mo X, Daelemans D, Sandanayaka V, Shechter S, McCauley D, Shacham S, Kauffman M, Chook YM, Byrd JC. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood. 2012 Nov 29;120(23):4621-34. doi: 10.1182/blood-2012-05-429506. Epub 2012 Oct 3.
Reference Type
BACKGROUND
Lassen UN, Mau-Soerensen M, Kung AL, Wen PY, Lee EQ, Plotkin SR, et al. A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM). J Clin Oncol 33, 2015 (suppl; abstr 2044)
Reference Type
BACKGROUND
Noske A, Weichert W, Niesporek S, Roske A, Buckendahl AC, Koch I, Sehouli J, Dietel M, Denkert C. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer. 2008 Apr 15;112(8):1733-43. doi: 10.1002/cncr.23354.
Reference Type
BACKGROUND
Pathria G, Wagner C, Wagner SN. Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways. J Invest Dermatol. 2012 Dec;132(12):2780-90. doi: 10.1038/jid.2012.233. Epub 2012 Jul 26.
Reference Type
BACKGROUND
Saito N, Sakakibara K, Sato T, Friedman JM, Kufe DW, VonHoff DD, Kawabe T. CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway. Mol Cancer Ther. 2014 Dec;13(12):3013-23. doi: 10.1158/1535-7163.MCT-14-0064. Epub 2014 Sep 24.
Reference Type
BACKGROUND
Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM, Kufe DW, Vonhoff DD, Iwami T, Kawabe T. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood. 2011 Oct 6;118(14):3922-31. doi: 10.1182/blood-2011-01-333138. Epub 2011 Aug 12.
Reference Type
BACKGROUND
Senapedis WT, Baloglu E, Landesman Y. Clinical translation of nuclear export inhibitors in cancer. Semin Cancer Biol. 2014 Aug;27:74-86. doi: 10.1016/j.semcancer.2014.04.005. Epub 2014 Apr 19.
Reference Type
BACKGROUND
Siddiqui N, Borden KL. mRNA export and cancer. Wiley Interdiscip Rev RNA. 2012 Jan-Feb;3(1):13-25. doi: 10.1002/wrna.101. Epub 2011 Jul 27.
Reference Type
BACKGROUND
Storer BE. Design and analysis of phase I clinical trials. Biometrics. 1989 Sep;45(3):925-37.
Reference Type
BACKGROUND
Tan DS, Bedard PL, Kuruvilla J, Siu LL, Razak AR. Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy. Cancer Discov. 2014 May;4(5):527-37. doi: 10.1158/2159-8290.CD-13-1005. Epub 2014 Apr 17.
Reference Type
BACKGROUND
Tan DSP, Pang M-Y, Yong WP, Soo RA, Chee CE, Thian YL et al. Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers. J Clin Oncol 33, 2015 (suppl; abstr 2542).
Reference Type
BACKGROUND
Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol. 2012 Apr 15;83(8):1021-32. doi: 10.1016/j.bcp.2011.12.016. Epub 2011 Dec 20.
Reference Type
BACKGROUND
van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, Birrer MJ, Leaner VD. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer. 2009 Apr 15;124(8):1829-40. doi: 10.1002/ijc.24146.
Reference Type
BACKGROUND
Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, Milojkovic D, Goldman JM, Apperley J, Garzon R, Marcucci G, Shacham S, Kauffman MG, Perrotti D. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood. 2013 Oct 24;122(17):3034-44. doi: 10.1182/blood-2013-04-495374. Epub 2013 Aug 22.
Reference Type
BACKGROUND
Wang W, Budhu A, Forgues M, Wang XW. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol. 2005 Aug;7(8):823-30. doi: 10.1038/ncb1282. Epub 2005 Jul 24.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STML-801-0115
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Penclomedine in Treating Patients With Advanced Solid Tumors
NCT00002915
COMPLETED
PHASE1
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
NCT05388435
TERMINATED
PHASE1/PHASE2
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
NCT06403436
RECRUITING
PHASE1
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
NCT05268666
UNKNOWN
PHASE1/PHASE2
Study of XL820 in Adults With Solid Tumors
NCT00129571
COMPLETED
PHASE1
Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors
NCT00003713
COMPLETED
PHASE1
A Phase 1 Study of S-3304 in Patients With Solid Tumors
NCT00033215
COMPLETED
PHASE1
A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors
NCT05258266
UNKNOWN
PHASE1/PHASE2
Decitabine in Treating Patients With Advanced Solid Tumors
NCT00030615
COMPLETED
PHASE1
Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors
NCT07310134
RECRUITING
PHASE1
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
NCT05037149
ACTIVE_NOT_RECRUITING
PHASE1
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
NCT02419495
TERMINATED
PHASE1
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
NCT01552356
ACTIVE_NOT_RECRUITING
PHASE1
Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors
NCT01014429
COMPLETED
PHASE1
CHS 828 in Treating Patients With Solid Tumors
NCT00003979
WITHDRAWN
PHASE1
A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
NCT00422097
COMPLETED
PHASE1
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
NCT04587479
COMPLETED
PHASE1
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
NCT05118841
UNKNOWN
PHASE1
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
NCT04317105
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors
NCT05181865
WITHDRAWN
PHASE1/PHASE2
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
NCT05142592
RECRUITING
PHASE1/PHASE2
Oral ONC201 in Treating Patients With Advanced Solid Tumors
NCT02250781
COMPLETED
PHASE1
First In Human Study of CX-801 in Advanced Solid Tumors
NCT06462794
RECRUITING
PHASE1
Irinotecan in Treating Patients With Advanced Solid Tumors
NCT00004051
COMPLETED
PHASE1
XTX301 in Patients With Advanced Solid Tumors
NCT05684965
RECRUITING
PHASE1/PHASE2